Cat 1 — 2026Skin & hairLongevity

Argireline

Acetyl Hexapeptide-3 / Acetyl Hexapeptide-8

Topical SNARE-inhibiting peptide that reduces facial expression lines by decreasing muscle contraction intensity. Often called a Botox alternative. Multiple human RCTs with wrinkle reduction data.

Evidence

Strong clinical data

Routes

topical

Available since

Developed by Lipotec in late 1990s. Widespread commercial cosmetic use from early 2000s.

Mechanism of action

Inhibits SNARE complex formation at neuromuscular junctions. Blocks acetylcholine release at nerve terminals reducing muscle contraction intensity without paralysis. Penetrates stratum corneum when formulated correctly at adequate concentration.

Effects in the body

Argireline reduces the intensity of facial muscle contractions rather than paralysing them like botulinum toxin. More subtle and fully reversible. Works specifically on expression lines from repetitive muscle movement — forehead frown lines and eye area.

Pros & cons (from the literature)

Pros

Multiple human clinical studies showing measurable wrinkle reduction
No injection required — topical application
Reversible and safe no paralysis risk
Widely available in commercial formulations
Well characterized mechanism

Cautions

Effects subtle compared to botulinum toxin
Limited to surface expression lines
Requires consistent daily use for maintained results
Cosmetic only no therapeutic claims
Many products underdose — concentration matters

Protocol summary (from published research)

Topical 5-10% concentration applied twice daily. Most effective on forehead and eye area expression lines. Best used in combination with Matrixyl for complementary mechanisms.

Dosing ranges reproduced from published research literature. Not a prescription, not medical advice.

FDA & regulatory status

Regulated as a cosmetic ingredient not a drug. No FDA drug approval required for topical cosmetic use. One of the most commercially validated topical peptides with genuine human clinical evidence.

Evidence base

Multiple double-blind clinical studies published. Rona et al. 2002 published key efficacy data. Well replicated in independent studies.

Primary research sources

Peer-reviewed literature referenced throughout this profile is drawn from PubMed, Cell Metabolism, and clinical trial registries cited in the evidence base above.

Important. ThePeptide.expert summarizes published research. We are not a pharmacy, do not prescribe, and make no therapeutic claims. Regulatory status varies by jurisdiction.